2,080 IQVIA Holdings Inc. $IQV Shares Sold by Nippon Life Global Investors Americas Inc.

Nippon Life Global Investors Americas Inc. cut its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 48.4% during the 3rd quarter, HoldingsChannel reports. The fund owned 2,220 shares of the medical research company’s stock after selling 2,080 shares during the quarter. Nippon Life Global Investors Americas Inc.’s holdings in IQVIA were worth $597,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of IQV. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of IQVIA in the third quarter worth $12,510,000. Vise Technologies Inc. lifted its stake in IQVIA by 17.2% during the third quarter. Vise Technologies Inc. now owns 9,601 shares of the medical research company’s stock worth $2,581,000 after purchasing an additional 1,411 shares during the last quarter. Avestar Capital LLC bought a new stake in IQVIA during the third quarter worth $320,000. Parcion Private Wealth LLC increased its stake in shares of IQVIA by 13.9% in the 3rd quarter. Parcion Private Wealth LLC now owns 1,312 shares of the medical research company’s stock valued at $353,000 after purchasing an additional 160 shares during the last quarter. Finally, Soltis Investment Advisors LLC acquired a new position in shares of IQVIA during the 3rd quarter worth $461,000. 89.62% of the stock is owned by institutional investors.

IQVIA Stock Down 0.1%

Shares of NYSE IQV opened at $266.93 on Monday. The company has a 50 day simple moving average of $266.22 and a 200 day simple moving average of $210.41. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.83 and a quick ratio of 0.83. IQVIA Holdings Inc. has a 1 year low of $154.50 and a 1 year high of $284.50. The firm has a market cap of $43.99 billion, a PE ratio of 32.43, a price-to-earnings-growth ratio of 2.38 and a beta of 1.16.

IQVIA (NYSE:IQV) last posted its earnings results on Tuesday, October 27th. The medical research company reported $3.34 earnings per share for the quarter, topping analysts’ consensus estimates of $3.26 by $0.08. IQVIA had a net margin of 8.05% and a return on equity of 30.02%. The firm had revenue of $4.43 billion for the quarter, compared to analyst estimates of $4.37 billion. During the same period in the previous year, the firm posted $3.00 EPS. The company’s revenue for the quarter was up 8.0% compared to the same quarter last year. On average, research analysts forecast that IQVIA Holdings Inc. will post 11.53 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on IQV shares. UBS Group started coverage on shares of IQVIA in a research note on Wednesday, September 30th. They issued a “buy” rating and a $345.00 price target on the stock. TD Cowen upped their price target on shares of IQVIA from $288.00 to $307.00 and gave the stock a “buy” rating in a report on Thursday. Deutsche Bank Aktiengesellschaft dropped their price target on IQVIA from $191.00 to $179.00 in a research note on Thursday, October 15th. BMO Capital Markets increased their price target on IQVIA from $270.00 to $305.00 in a research note on Monday, October 19th. Finally, William Blair upgraded IQVIA to a “strong-buy” rating in a research report on Tuesday, July 28th. Two analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $294.21.

Insider Activity at IQVIA

In related news, insider James G. Berkshire sold 2,668 shares of the business’s stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $261.33, for a total value of $697,228.44. Following the sale, the insider owned 10,890 shares of the company’s stock, valued at $2,845,883.70. The trade was a 19.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 1.70% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc is a global provider of technology, analytics and contract research services for the life sciences industry. The company helps pharmaceutical, biotechnology and medical device organizations develop, commercialize and improve products by combining healthcare data with advanced analytics, consulting and technology-enabled services.

Its offerings include clinical research and trial management, real-world evidence, healthcare data and analytics, regulatory and safety services, technology platforms, and commercial solutions.